LAG3 Inhibitors Change The Landscape Of Immunotherapy
A new immunotherapy checkpoint inhibitor targeting LAG3, relatlimab, shows promising results when given as a fixed-dose combination with the PD-1 inhibitor nivolumab for the treatment of metastatic melanoma in patients with low PD-L1 expression.
